Skip to main content

Loading market data...

INDV

Indivior Pharmaceuticals, Inc.

NASDAQ • United states

$35.04

+$0.27

(+0.78%)

Source: Yahoo Finance · Quote time Oct 21, 2026 14:48 GMT+0000

Management
Credibility
Score

Indivior Pharmaceuticals, Inc. (INDV)

Unavailable

Quotes may be delayed

$4.14B

Market Cap

154,756

Volume

11.7

P/E Ratio

Unavailable

Div Yield

Indivior Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 234 BATH ROAD, SLOUGH, BERKSHIRE, X0
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

16 Oct 2026

Indivior PLC reported Shareholder voting results

Indivior PLC filed an 8-K covering shareholder voting results.

6 Oct 2026

Indivior PLC business combination filing

Indivior PLC filed Form 425 (communications about a business combination).

6 Oct 2026

Indivior PLC reported Another company event

Indivior PLC filed an 8-K covering another company event.

1 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Indivior PLC.

17 Sep 2026

Indivior PLC business combination filing

Indivior PLC filed Form 425 (communications about a business combination).

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$222.00M

Total assets (USD)$1.23B

Total liabilities (USD)$1.44B

Shareholders' equity (USD)−$208.00M

Long-term debt (USD)$487.00M

Debt due within a year (USD)$0

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$343.00M	$160.00M	$122.00M	$0.98	10-Q · 3 Aug 2026
Q1 2026	$317.00M	$137.00M	$89.00M	$0.69	10-Q · 30 Apr 2026
Q4 2025	$358.00M	$81.00M	$102.00M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$314.00M	$43.00M	$42.00M	$0.33	10-Q · 30 Oct 2025
Q2 2025	$302.00M	$72.00M	$18.00M	$0.14	10-Q · 31 Jul 2025
Q1 2025	$266.00M	$66.00M	$47.00M	$0.38	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $45.50

29.9% upside potential

📈

Strong Buy

Unavailable

👍

Buy

3

⏸️

Hold

0

📉

Sell

0

3 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 14:49 UTC Targets range 43.00–48.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

27

Aug 2026

Anderson Woodrow D

Chief Accounting Officer

Open-market purchase

$35.69 per share

1,500 shares

5

Aug 2026

Anderson Woodrow D

Chief Accounting Officer

Open-market purchase

$36.28 per share

1,500 shares

10

Jul 2026

Heidbreder Christian

Chief Scientific Officer

Open-market sale

$41.14 per share

18,586 shares

22

Jun 2026

Ciaffoni Joseph

Director, Chief Executive Officer

Option exercise

Unavailable per share

1,266,903 shares

22

Jun 2026

Ciaffoni Joseph

Director, Chief Executive Officer

Tax withholding

$38.32 per share

612,549 shares

11

Jun 2026

Heidbreder Christian

Chief Scientific Officer

Open-market sale

$38.06 per share

18,586 shares

8

Jun 2026

Preblick Ryan

Chief Financial Officer

Open-market sale

$37.70 per share

36,000 shares

13

May 2026

Thompson Juliet

Director

Grant or award

Unavailable per share

6,518 shares

13

May 2026

Humphreys Keith

Director

Grant or award

Unavailable per share

6,518 shares

12

May 2026

Thompson Juliet

Director

Tax withholding

$38.28 per share

1,117 shares

Top Shareholders

Blackrock, Inc.

18,709,432 shares

0.902% change

6/30/2026

Vanguard Portfolio Management Llc

7,572,287 shares

-4.049% change

6/30/2026

Oaktree Capital Management Lp

6,127,212 shares

-12.269% change

6/30/2026

Vanguard Capital Management Llc

5,495,486 shares

-1.631% change

6/30/2026

Vanguard Group Inc

5,473,891 shares

57.94% change

12/31/2025

State Street Corp

4,992,071 shares

1.796% change

6/30/2026

Fuller & Thaler Asset Management, Inc.

4,615,816 shares

1.904% change

6/30/2026

Two Seas Capital Lp

3,671,072 shares

5.506% change

9/30/2026

Assenagon Asset Management S.A.

3,540,344 shares

129.754% change

9/30/2026

Morgan Stanley

3,395,702 shares

-3.141% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 14:49 UTC· 16 hours ago

Research coverage and investment tools

Indivior Pharmaceuticals, Inc. (INDV) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$35.04 on 21 Oct 2026. That is 59% of the way from its 52-week low of US$24.03 to its 52-week high of US$42.81. Its market capitalisation was US$4.14 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$343.00M	$160.00M	$122.00M	$0.98	85.7%	46.6%	$222.00M	10-Q · 3 Aug 2026 (opens in a new tab)
Q1 2026	$317.00M	$137.00M	$89.00M	$0.69	87.4%	43.2%	−$29.00M	10-Q · 30 Apr 2026 (opens in a new tab)
Q4 2025	$358.00M	$81.00M	$102.00M	Unavailable	81.6%	22.6%	−$245.00M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$314.00M	$43.00M	$42.00M	$0.33	73.2%	13.7%	−$59.00M	10-Q · 30 Oct 2025 (opens in a new tab)
Q2 2025	$302.00M	$72.00M	$18.00M	$0.14	82.8%	23.8%	$141.00M	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$266.00M	$66.00M	$47.00M	$0.38	83.1%	24.8%	$70.00M	10-Q · 1 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	8/3/2026	$1.15	$0.97	+18.6%
Mar 2026	4/30/2026	$0.96	$0.64	+50.0%
Dec 2025	2/26/2026	$0.82	$0.65	+26.2%
Sep 2025	10/30/2025	$0.72	$0.38	+89.5%

Cash and equivalents: $222.00M
Total assets: $1.23B
Total liabilities: $1.44B
Shareholders' equity: −$208.00M
Long-term debt: $487.00M
Debt due within a year: $0

8-K · 16 Oct 2026

Indivior PLC reported Shareholder voting results (opens in a new tab)

Indivior PLC filed an 8-K covering shareholder voting results.
425 · 6 Oct 2026 · Merger or acquisition Announced

Indivior PLC business combination filing (opens in a new tab)

Indivior PLC filed Form 425 (communications about a business combination).
8-K · 6 Oct 2026

Indivior PLC reported Another company event (opens in a new tab)

Indivior PLC filed an 8-K covering another company event.
SCHEDULE 13G · 1 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Indivior PLC.
425 · 17 Sep 2026 · Merger or acquisition Announced

Indivior PLC business combination filing (opens in a new tab)

Indivior PLC filed Form 425 (communications about a business combination).

Insider	Date	Transaction	Shares	Average price	Filing
Anderson Woodrow D Chief Accounting Officer	27 Aug 2026	Open-market purchase (P)	+1,500	$35.69	Form 4 (opens in a new tab)
Anderson Woodrow D Chief Accounting Officer	5 Aug 2026	Open-market purchase (P)	+1,500	$36.28	Form 4 (opens in a new tab)
Heidbreder Christian Chief Scientific Officer	10 Jul 2026	Open-market sale (S)	−18,586	$41.14	Form 4 (opens in a new tab)
Ciaffoni Joseph Director, Chief Executive Officer	22 Jun 2026	Option exercise (M)	+1,266,903	—	Form 4 (opens in a new tab)
Ciaffoni Joseph Director, Chief Executive Officer	22 Jun 2026	Tax withholding (F)	−612,549	$38.32	Form 4 (opens in a new tab)
Heidbreder Christian Chief Scientific Officer	11 Jun 2026	Open-market sale (S)	−18,586	$38.06	Form 4 (opens in a new tab)
Preblick Ryan Chief Financial Officer	8 Jun 2026	Open-market sale (S)	−36,000	$37.70	Form 4 (opens in a new tab)
Thompson Juliet Director	13 May 2026	Grant or award (A)	+6,518	—	Form 4 (opens in a new tab)
Humphreys Keith Director	13 May 2026	Grant or award (A)	+6,518	—	Form 4 (opens in a new tab)
Thompson Juliet Director	12 May 2026	Tax withholding (F)	−1,117	$38.28	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	18,709,432	0.902%
Vanguard Portfolio Management Llc	6/30/2026	7,572,287	-4.049%
Oaktree Capital Management Lp	6/30/2026	6,127,212	-12.269%
Vanguard Capital Management Llc	6/30/2026	5,495,486	-1.631%
Vanguard Group Inc	12/31/2025	5,473,891	57.94%
State Street Corp	6/30/2026	4,992,071	1.796%
Fuller & Thaler Asset Management, Inc.	6/30/2026	4,615,816	1.904%
Two Seas Capital Lp	9/30/2026	3,671,072	5.506%
Assenagon Asset Management S.A.	9/30/2026	3,540,344	129.754%
Morgan Stanley	6/30/2026	3,395,702	-3.141%

Previous close: 34.77 USD
Day range: 34.67 – 35.15 USD
52-week range: 24.03 – 42.81 USD
Volume: 154,756
Market cap: $4.14B
Average volume: 2,202,902
P/E ratio: 11.7
EPS (FY 2025, diluted): 1.64 USD
Shares outstanding: 118.03M
Beta (5Y monthly): 1.13

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 21 Oct 2026, 14:48 UTC· 16 hours ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:26 UTC· 46 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for INDV yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.